TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Acquires 4,826 Shares

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela purchased 4,826 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were acquired at an average cost of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the acquisition, the chief executive officer now owns 429,503 shares of the company’s stock, valued at approximately $2,327,906.26. This trade represents a 1.14 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

TriSalus Life Sciences Stock Performance

Shares of TriSalus Life Sciences stock opened at $4.93 on Thursday. The stock has a market cap of $150.32 million, a price-to-earnings ratio of -1.98 and a beta of 0.51. The stock has a 50 day moving average price of $4.55 and a 200-day moving average price of $4.75. TriSalus Life Sciences, Inc. has a one year low of $3.50 and a one year high of $10.42.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Walleye Capital LLC purchased a new stake in shares of TriSalus Life Sciences in the third quarter valued at $66,000. Virtu Financial LLC purchased a new position in shares of TriSalus Life Sciences during the 3rd quarter worth about $92,000. Vestcor Inc bought a new position in TriSalus Life Sciences during the 3rd quarter valued at about $108,000. MSD Partners L.P. purchased a new stake in TriSalus Life Sciences in the 3rd quarter worth about $184,000. Finally, Geode Capital Management LLC lifted its stake in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective on the stock. Roth Mkm restated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Finally, Canaccord Genuity Group dropped their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $11.79.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.